Michael Andrew Chambers, Director at Sarepta Therapeutics, Inc. (SRPT), bought 47,372 shares at $108.05 ($5.1M) on 2023-08-11, disclosed to the SEC on 2023-08-14.
Open-market purchase of $5.1M SRPT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $108.05 | 23,686 | $2.6M | 50.0% |
| 2 | $108.05 | 23,686 | $2.6M | 50.0% |
| Total | $108.05 avg | 47,372 | $5.1M | 100% |
| Filing → |
| SRPT | BUY | 2023-08-11 | $7.4M | — | Filing → |
| SRPT | BUY | 2022-09-15 | $11.3M | — | Filing → |
| SRPT | BUY | 2022-08-22 | $5.0M | — | Filing → |